الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
Coronavirus disease 2019 (Covid-19) is an illness caused by
severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). It
primarily affects the lungs resulting in inflammation and pneumonia.
Covid-19 is associated with a higher risk of thrombotic
complications and a greater magnitude of these events than are other
respiratory infections. A thromboinflammatory state, associated with
endothelial dysfunction, hypercoagulability, and coagulation activation,
leads to an increased risk of microvascular and macrovascular thrombosis.
These thrombotic complications include arterial and venous events, with
microvascular thrombosis possibly contributing to the diffuse lung injury
seen in patients with COVID-19.
Given the reports of excess thrombotic risk, enhanced-dose
anticoagulation strategies have been incorporated into some Covid-19
guidance statements, especially for critically ill patients. However, the
effectiveness and safety of therapeutic-dose anticoagulation given to
improve outcomes in Covid-19 are uncertain.
Summary of our results:
regarding the baseline data there was no statistically significant
difference detected between both treatment arms regarding baseline
characteristics (age, sex distribution, BMI, comorbidities, time from
symptoms onset and baseline laboratory data (Hb, PLT, creatinine,
BUN, ALT, INR, D-dimer, ferritin, procalcitonin, CRP and
PaO2/FiO2).
Regarding the efficacy outcome by clinical status assessed by the
ordinal scale of who, there was no statistically significant difference
between both groups at any time point for 2 weeks.
Regarding CBC test results, kidney function tests, ALT, ferritin,
procalcitonin, CRP and INR evidenced no statically significant
difference between both groups at any timepoint for 2 weeks.
As for D-dimer, it was insignificantly different at baseline and after
one week, meanwhile, we observed a significant difference after 2
weeks as it was lower in therapeutic anticoagulation group compared
to the prophylactic anticoagulation one.
Regarding ABG, PaO2/FiO2 level was insignificantly different
between both groups at baseline and after one week but after 2 weeks,
patients on therapeutic dose anticoagulation elicited significantly
increased PaO2/FiO2 ratio than those on prophylactic dose
anticoagulation.
The incidence of thromboembolic events was insignificantly different
between both groups at any time point for 2 weeks.
Regarding 28-day mortality, we didn’t observe any statistically
significant difference between both groups.
Regarding the need for MV, renal replacement therapy, vasopressor
need, and length of hospital stay there was no statistically significant
difference between both groups.
Regarding major bleeding, only 8.6% of the therapeutic
anticoagulation group experienced major bleeding, with no
statistically significant difference between both groups.
Kaplan Meier analysis showed that patients on therapeutic-dose
anticoagulation had a slightly lower probability of mortality than
those on prophylactic-dose anticoagulation, but with no statistically
significant difference.
In both groups, there was a significant positive correlation between
WHO ordinal scale for clinical status and each of INR, D-dimer, ferritin, procalcitonin and CRP after 2 weeks of treatment. On the
other hand, there was a significant negative correlation between
WHO scale and PaO2/FiO2.